English Polski

Wyszuk. zaawans.

Tom 25, Nr 1-2 (2023)
Artykuł poglądowy
Opublikowany online: 2024-09-13

dostęp otwarty

Pokaż PDF Pobierz plik PDF
Wyświetlenia strony 105
Wyświetlenia/pobrania artykułu 147
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Diagnostyka i leczenie glejaków drogi wzrokowej. Przegląd piśmiennictwa

Zuzanna Paluch12, Michał Szymoniuk2, Michalina Pytka3, Paweł Kozyra4, Anna Drelich-Zbroja5
DOI: 10.5603/chp.95315
Chirurgia Polska 2023;25(1-2):38-47.

Streszczenie

Glejaki drogi wzrokowej (OPGs, optic pathway gliomas) to pierwotne nowotwory ośrodkowego układu
nerwowego o niskim stopniu złośliwości, występujące najczęściej u dzieci oraz u młodych dorosłych.
OPG może pojawiać się sporadycznie lub w przebiegu neurofibromatozy typu 1. Obraz kliniczny może
różnić się w zależności od lokalizacji i wielkości guza. OPG może zarówno przebiegać bezobjawowo, jak
i dawać objawy okulistyczne, takie jak jednostronny wytrzeszcz lub zaburzenia widzenia. Chociaż glejaki
drogi wzrokowej są guzami o niskim stopniu złośliwości, mogą być agresywne, a ich leczenie często
stanowi wyzwanie. Postępowanie w przypadku tych guzów jest wysoce zindywidualizowane. Zależy ono
od charakteru i rozległości zmiany oraz funkcji wzrokowej. Może obejmować obserwację zachowawczą,
chemioterapię, radioterapię lub interwencję chirurgiczną.

Słowa kluczowe: glejak nerwu wzrokowegoneurofibromatoza typu 1diagnostykaleczenie

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Farazdaghi MK, Katowitz WR, Avery RA. Current treatment of optic nerve gliomas. Curr Opin Ophthalmol. 2019; 30(5): 356–363.
    CrossRefPubMed
  2. Rasool N, Odel JG, Kazim M. Optic pathway glioma of childhood. Curr Opin Ophthalmol. 2017; 28(3): 289–295.
    CrossRefPubMed
  3. Park ES, Park JB, Ra YS. Pediatric glioma at the optic pathway and thalamus. J Korean Neurosurg Soc. 2018; 61(3): 352–362.
    CrossRefPubMed
  4. Nair AG, Pathak RS, Iyer VR, et al. Optic nerve glioma: an update. Int Ophthalmol. 2014; 34(4): 999–1005.
    CrossRefPubMed
  5. Campen CJ, Gutmann DH. Optic pathway gliomas in neurofibromatosis type 1. J Child Neurol. 2018; 33(1): 73–81.
    CrossRefPubMed
  6. Aihara Y, Chiba K, Eguchi S, et al. Pediatric optic pathway/hypothalamic glioma. Neurol Med Chir (Tokyo). 2018; 58(1): 1–9.
    CrossRefPubMed
  7. Dodge HW, Love JG, Craig WM. Gliomas of the optic nerves. AMA Arch Neurol Psychiatry. 1958; 79(6): 607–621.
    CrossRefPubMed
  8. Fried I, Tabori U, Tihan T, et al. Optic pathway gliomas: a review. CNS Oncol. 2013; 2(2): 143–159.
    CrossRefPubMed
  9. Shapey J, Danesh-Meyer HV, Kaye AH. Diagnosis and management of optic nerve glioma. J Clin Neurosci. 2011; 18(12): 1585–1591.
    CrossRefPubMed
  10. Purohit BS, Vargas MI, Ailianou A, et al. Orbital tumours and tumour-like lesions: exploring the armamentarium of multiparametric imaging. Insights Imaging. 2016; 7(1): 43–68.
    CrossRefPubMed
  11. Cassina M, Frizziero L, Opocher E, et al. Optic pathway glioma in type 1 neurofibromatosis: review of its pathogenesis, diagnostic assessment, and treatment recommendations. Cancers (Basel). 2019; 11(11).
    CrossRefPubMed
  12. Sellmer L, Farschtschi S, Marangoni M, et al. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1. Orphanet J Rare Dis. 2018; 13(1): 62.
    CrossRefPubMed
  13. Listernick R, Ferner RE, Liu GT, et al. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol. 2007; 61(3): 189–198.
    CrossRefPubMed
  14. Trevisson E, Cassina M, Opocher E, et al. Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1. J Neurooncol. 2017; 134(2): 279–287.
    CrossRefPubMed
  15. Blanchard G, Lafforgue MP, Lion-François L, et al. NF France network. Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort. Eur J Paediatr Neurol. 2016; 20(2): 275–281.
    CrossRefPubMed
  16. Listernick R, Louis DN, Packer RJ, et al. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol. 1997; 41(2): 143–149.
    CrossRefPubMed
  17. Evans DG, Salvador H, Chang VY, et al. Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1. Clin Cancer Res. 2017; 23(12): e46–e53.
    CrossRefPubMed
  18. Prada CE, Hufnagel RB, Hummel TR, et al. The use of magnetic resonance imaging screening for optic pathway gliomas in children with neurofibromatosis type 1. J Pediatr. 2015; 167(4): 851–856.e1.
    CrossRefPubMed
  19. Chung EM, Specht CS, Schroeder JW. From the archives of the AFIP: Pediatric orbit tumors and tumorlike lesions: neuroepithelial lesions of the ocular globe and optic nerve. Radiographics. 2007; 27(4): 1159–1186.
    CrossRefPubMed
  20. Becker M, Masterson K, Delavelle J, et al. Imaging of the optic nerve. Eur J Radiol. 2010; 74(2): 299–313.
    CrossRefPubMed
  21. Cummings TJ, Provenzale JM, Hunter SB, et al. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathol. 2000; 99(5): 563–570.
    CrossRefPubMed
  22. Barkovich AJ. Pediatric neuroimaging, 4th edn. Lippincott Williams & Wilkins, Philadelphia 2005: 875–884.
  23. Weber AL, Caruso P, Sabates NR. The optic nerve: radiologic, clinical, and pathologic evaluation. Neuroimaging Clin N Am. 2005; 15(1): 175–201.
    CrossRefPubMed
  24. Pungavkar SA, Lawande MA, Patkar DP, et al. Bilateral optic pathway glioma with intracranial calcification: magnetic resonance imaging and magnetic resonance spectroscopy findings. Australas Radiol. 2005; 49(6): 489–492.
    CrossRefPubMed
  25. Pepin SM, Lessell S. Anterior visual pathway gliomas: The last 30 years. Semin Ophthalmol. 2006; 21(3): 117–124.
    CrossRefPubMed
  26. Miller NR. Primary tumours of the optic nerve and its sheath. Eye (Lond). 2004; 18(11): 1026–1037.
    CrossRefPubMed
  27. Wilhelm H. Primary optic nerve tumours. Curr Opin Neurol. 2009; 22(1): 11–18.
    CrossRefPubMed
  28. Dutton JJ. Gliomas of the anterior visual pathway. Surv Ophthalmol. 1994; 38(5): 427–452.
    CrossRefPubMed
  29. Ge M, Li S, Wang L, et al. The role of diffusion tensor tractography in the surgical treatment of pediatric optic chiasmatic gliomas. J Neurooncol. 2015; 122(2): 357–366.
    CrossRefPubMed
  30. Yeom KW, Lober RM, Andre JB, et al. Prognostic role for diffusion-weighted imaging of pediatric optic pathway glioma. J Neurooncol. 2013; 113(3): 479–483.
    CrossRefPubMed
  31. Parrozzani R, Clementi M, Kotsafti O, et al. Optical coherence tomography in the diagnosis of optic pathway gliomas. Invest Ophthalmol Vis Sci. 2013; 54(13): 8112–8118.
    CrossRefPubMed
  32. Parrozzani R, Miglionico G, Leonardi F, et al. Correlation of peripapillary retinal nerve fibre layer thickness with visual acuity in paediatric patients affected by optic pathway glioma. Acta Ophthalmol. 2018; 96(8): e1004–e1009.
    CrossRefPubMed
  33. Avery RA, Mansoor A, Idrees R, et al. Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1. Neurology. 2016; 87(23): 2403–2407.
    CrossRefPubMed
  34. Avery RA, Cnaan A, Schuman JS, et al. Longitudinal change of circumpapillary retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol. 2015; 160(5): 944–952.e1.
    CrossRefPubMed
  35. Liu Y, Hao X, Liu W, et al. Analysis of survival prognosis for children with symptomatic optic pathway gliomas who received surgery. World Neurosurg. 2018; 109: e1–e15.
    CrossRefPubMed
  36. Avery RA, Fisher MJ, Liu GT. Optic pathway gliomas. J Neuroophthalmol. 2011; 31(3): 269–278.
    CrossRefPubMed
  37. Liu GT. Optic gliomas of the anterior visual pathway. Curr Opin Ophthalmol. 2006; 17(5): 427–431.
    CrossRefPubMed
  38. Borghei-Razavi H, Shibao S, Schick U. Prechiasmatic transection of the optic nerve in optic nerve glioma: technical description and surgical outcome. Neurosurg Rev. 2017; 40(1): 135–141.
    CrossRefPubMed
  39. Reddy AT, Witek K. Neurologic complications of chemotherapy for children with cancer. Curr Neurol Neurosci Rep. 2003; 3(2): 137–142.
    CrossRefPubMed
  40. Fisher MJ, Loguidice M, Gutmann DH, et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012; 14(6): 790–797.
    CrossRefPubMed
  41. Moreno L, Bautista F, Ashley S, et al. Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. Eur J Cancer. 2010; 46(12): 2253–2259.
    CrossRefPubMed
  42. Pollack IF. Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. J Neurosurg Pediatr. 2011; 8(2): 135–148.
    CrossRefPubMed
  43. Koutourousiou M, Gardner PA, Kofler JK, et al. Rare infundibular tumors: clinical presentation, imaging findings, and the role of endoscopic endonasal surgery in their management. J Neurol Surg B Skull Base. 2013; 74(1): 1–11.
    CrossRefPubMed
  44. Walker DA, Liu J, Kieran M, et al. CPN Paris 2011 Conference Consensus Group. A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro Oncol. 2013; 15(4): 462–468.
    CrossRefPubMed
  45. El Beltagy MA, Reda M, Enayet A, et al. Treatment and outcome in 65 children with optic pathway gliomas. World Neurosurg. 2016; 89: 525–534.
    CrossRefPubMed
  46. Goodden J, Pizer B, Pettorini B, et al. The role of surgery in optic pathway/hypothalamic gliomas in children. J Neurosurg Pediatr. 2014; 13(1): 1–12.
    CrossRefPubMed
  47. Mohammad AEN. En-Bloc resection versus resection after evacuation and suction of the content for orbital optic nerve glioma causing visual loss and disfiguring proptosis. Ophthalmic Plast Reconstr Surg. 2020; 36(4): 399–402.
    CrossRefPubMed
  48. Kaderbhai J, Lo W, Rodrigues D, et al. Craniofacial approaches to pediatric orbital tumors. J Craniofac Surg. 2019; 30(4): 1198–1200.
    CrossRefPubMed
  49. van Baarsen K, Roth J, Serova N, et al. Optic pathway-hypothalamic glioma hemorrhage: a series of 9 patients and review of the literature. J Neurosurg. 2018; 129(6): 1407–1415.
    CrossRefPubMed
  50. Kondo A, Akiyama O, Suzuki M, et al. A novel surgical approach for intraorbital optic nerve tumors. J Clin Neurosci. 2019; 59: 362–366.
    CrossRefPubMed
  51. Stella I, Helleringer M, Joud A, et al. Optic pathway tumor in children: toward a new classification for neurosurgical use. Neurochirurgie. 2021; 67(4): 336–345.
    CrossRefPubMed
  52. Shofty B, Ben-Sira L, Kesler A, et al. Optic pathway gliomas. Adv Tech Stand Neurosurg. 2015; 42: 123–146.
    CrossRefPubMed
  53. Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol. 2009; 24(11): 1397–1408.
    CrossRefPubMed
  54. Ahn Y, Cho BK, Kim SK, et al. Optic pathway glioma: outcome and prognostic factors in a surgical series. Childs Nerv Syst. 2006; 22(9): 1136–1142.
    CrossRefPubMed
  55. Mishra MV, Andrews DW, Glass J, et al. Characterization and outcomes of optic nerve gliomas: a population-based analysis. J Neurooncol. 2012; 107(3): 591–597.
    CrossRefPubMed
  56. Shriver EM, Ragheb J, Tse DT. Combined transcranial-orbital approach for resection of optic nerve gliomas: a clinical and anatomical study. Ophthalmic Plast Reconstr Surg. 2012; 28(3): 184–91.
    CrossRefPubMed
  57. Numa Y, Kawamoto K. Frontozygomatic approach to intraorbital tumors. Skull Base. 2007; 17(5): 303–310.
    CrossRefPubMed
  58. Zoli M, Mazzatenta D, Valluzzi A, et al. Expanding indications for the extended endoscopic endonasal approach to hypothalamic gliomas: preliminary report. Neurosurg Focus. 2014; 37(4): E11.
    CrossRefPubMed
  59. Somma T, Solari D, Beer-Furlan A, et al. Endoscopic endonasal management of rare sellar lesions: clinical and surgical experience of 78 cases and review of the literature. World Neurosurg. 2017; 100: 369–380.
    CrossRefPubMed
  60. Bin Abdulqader S, Al-Ajlan Z, Albakr A, et al. Endoscopic transnasal resection of optic pathway pilocytic astrocytoma. Childs Nerv Syst. 2019; 35(1): 73–81.
    CrossRefPubMed
  61. Graffeo CS, Dietrich AR, Grobelny B, et al. A panoramic view of the skull base: systematic review of open and endoscopic endonasal approaches to four tumors. Pituitary. 2014; 17(4): 349–356.
    CrossRefPubMed
  62. Kasemsiri P, Carrau RL, Ditzel Filho LFS, et al. Advantages and limitations of endoscopic endonasal approaches to the skull base. World Neurosurg. 2014; 82(6 Suppl): S12–S21.
    CrossRefPubMed
  63. Stapleton AL, Tyler-Kabara EC, Gardner PA, et al. Risk factors for cerebrospinal fluid leak in pediatric patients undergoing endoscopic endonasal skull base surgery. Int J Pediatr Otorhinolaryngol. 2017; 93: 163–166.
    CrossRefPubMed
  64. Chivukula S, Koutourousiou M, Snyderman CH, et al. Endoscopic endonasal skull base surgery in the pediatric population. J Neurosurg Pediatr. 2013; 11(3): 227–241.
    CrossRefPubMed
  65. Giovannetti F, Mussa F, Priore P, et al. Endoscopic endonasal skull base surgery in pediatric patients. A single center experience. J Craniomaxillofac Surg. 2018; 46(12): 2017–2021.
    CrossRefPubMed
  66. Ater J. Results of COG protocol A9952 : a randomized phase 3 study of two chemotherapy regimens for incompletely resected low-grade glioma in young children. Neuro Oncol. 2008; 10: 451.
  67. Ater JL, Xia C, Mazewski CM, et al. Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: a report from the children's oncology group. Cancer. 2016; 122(12): 1928–1936.
    CrossRefPubMed
  68. Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012; 30(12): 1358–1363.
    CrossRefPubMed
  69. Lassaletta A, Scheinemann K, Zelcer SM, et al. Phase II weekly vinblastine for chemotherapy-naïve children with progressive low-grade glioma: a Canadian pediatric brain tumor consortium study. J Clin Oncol. 2016; 34(29): 3537–3543.
    CrossRefPubMed
  70. Devereux S, Selassie TG, Vaughan Hudson G, et al. Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation. BMJ. 1990; 301(6760): 1077–1080.
    CrossRefPubMed
  71. Leone G, Mele L, Pulsoni A, et al. The incidence of secondary leukemias. Haematologica. 1999; 84(10): 937–945.
    PubMed
  72. Perry JR, Brown MT, Gockerman JP. Acute leukemia following treatment of malignant glioma. J Neurooncol. 1998; 40(1): 39–46.
    CrossRefPubMed
  73. Maris JM, Wiersma SR, Mahgoub N, et al. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer. 1997; 79(7): 1438–1446.
    PubMed
  74. Matsui I, Tanimura M, Kobayashi N, et al. Neurofibromatosis type 1 and childhood cancer. Cancer. 1993; 72(9): 2746–2754, doi: 10.1002/1097-0142(19931101)72:9<2746::aid-cncr2820720936>3.0.co;2-w.
    PubMed
  75. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med. 1994; 330(9): 597–601.
    CrossRefPubMed
  76. Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer. 1994; 70(5): 969–972.
    CrossRefPubMed
  77. Massimino M, Spreafico F, Cefalo G, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002; 20(20): 4209–4216.
    CrossRefPubMed
  78. Cardellicchio S, Bacci G, Farina S, et al. Low-dose cisplatin-etoposide regimen for patients with optic pathway glioma: a report of four cases and literature review. Neuropediatrics. 2014; 45(1): 42–49.
    CrossRefPubMed
  79. Cappellano AM, Petrilli AS, da Silva NS, et al. Single agent vinorelbine in pediatric patients with progressive optic pathway glioma. J Neurooncol. 2015; 121(2): 405–412.
    CrossRefPubMed
  80. Gururangan S, Fisher MJ, Allen JC, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007; 9(2): 161–168.
    CrossRefPubMed
  81. Banerjee A, Jakacki RI, Onar-Thomas A, et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol. 2017; 19(8): 1135–1144.
    CrossRefPubMed
  82. Bartels U, Hawkins C, Jing Ma, et al. Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas. J Neurosurg. 2006; 104(5 Suppl): 314–320.
    CrossRefPubMed
  83. Presta LG, Chen H. O’Connor SJ, at al. Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders. Cancer Res. 1997; 57(20): 4593–4599.
    PubMed
  84. Gururangan S, Fangusaro J, Poussaint TY, et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium Study. Neuro Oncol. 2014; 16(2): 310–317.
    CrossRefPubMed
  85. Hwang EI, Jakacki RI, Fisher MJ, et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer. 2013; 60(5): 776–782.
    CrossRefPubMed
  86. Falsini B, Chiaretti A, Rizzo D, et al. Nerve growth factor improves visual loss in childhood optic gliomas: a randomized, double-blind, phase II clinical trial. Brain. 2016; 139(Pt 2): 404–414.
    CrossRefPubMed
  87. Warrington NM, Gianino SM, Jackson E, et al. Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. Cancer Res. 2010; 70(14): 5717–5727.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Copyright © 2023-2024 Via Medica Regulamin Polityka cookies Polityka prywatności Nota prawna